← All indications
Uterine Neoplasms
Tumors or cancer of the UTERUS.
Subtype terms (2)
More specific conditions that are subtypes of Uterine Neoplasms in the MeSH hierarchy.
- Endometrial Neoplasms
487 drugs (188 approved, 299 experimental)
- Uterine Cervical Neoplasms
545 drugs (192 approved, 353 experimental)
Drugs by status
Phase 4 trials (4)
Phase 3 trials (18)
Phase 2 trials (100)
- fluorothymidine
- thalidomide
- saracatinib
- vitamin d3
- afatinib
- rucaparib
- atezolizumab
- mk-1775
- olaparib
- azd-4547
- urea
- sorafenib
- binimetinib
- brivanib alaninate
- temsirolimus
- dabrafenib
- doxycycline
- progesterone
- dkn-01
- durvalumab
- eribulin
- cannabidiol
- enzalutamide
- fulvestrant
- fluoroestradiol
- vismodegib
- gemcitabine
- fluorouracil
- imatinib
- trametinib
- +70 more
Phase 1 trials (21)
Organizations
Organization Involved with Phase 4 Indications (6)
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (58)
- Seattle Genetics
- Bristol-Myers Squibb
- Genmab
- Roche
- AstraZeneca
- Eli Lilly
- Genentech
- Sanofi
- Novartis
- Catalysis SL
- GlaxoSmithKline
- Gradalis, Inc.
- Hengrui Therapeutics, Inc.
- Leap Therapeutics, Inc.
- Pharmacia
- PharmaMar
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- Maastricht University
- Central South University
- Cornell University
- Harvard University
- ECOG-ACRIN Cancer Research Group
- University of Washington
- Gynecologic Oncology Group
- Hoosier Cancer Research Network
- New York University
- Radboud University
- Sarcoma Alliance for Research through Collaboration
- University of Groningen
- +28 more
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (4)